adea case series merlin thomas gary kilov nicole frayne giuliana murfet facilitator: rachel mckeown,...
TRANSCRIPT
![Page 1: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/1.jpg)
GLP-1 Receptor Agonists
ADEA CASE SERIES
Merlin ThomasGary KilovNicole Frayne Giuliana Murfet
Facilitator: Rachel McKeown,Professional Services Manager, ADEA (NSW)
![Page 2: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/2.jpg)
Motivated/adherentGood self-careShort durationLow hypo riskLong life expectancy No co-morbidityGood resources
Non-compliantPoor self-careLongstanding
High hypo riskShort life expectancy
Co-morbidityLimited resources
<7 COMPROMISETARGET
Adapted from Inzucchi et al Diabetes Care 2012
The right target...
![Page 3: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/3.jpg)
Motivated/adherentGood self-careShort durationLow hypo riskLong life expectancy No co-morbidityGood resources
Non-compliantPoor self-careLongstanding
High hypo riskShort life expectancy
Co-morbidityLimited resources
Standard ?Adapted from Inzucchi et al Diabetes Care 2012
….with the right agent
![Page 4: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/4.jpg)
How does GLP-1 lower glucose levels in diabetes?
1. BACKGROUND
![Page 5: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/5.jpg)
α
β
Incretins in -cell biology3,4
L
MEAL
GLPRGLP-1
Distal small intestine ileum and colon
Pancreas
• Amplified insulin secretion
• Improved glucose sensitivity
• -cell proliferation/neogenesis
• Reduced -cell apoptosis
3. Campbell & Drucker. Cell Metabolism (2013); 4. Diakogiannaki, et al. Physiol. Behav. (2012).
carbohydrate protein, fatty &
bile acids
vagal
Up to 70% of total post-prandial insulin production is determined by incretins
The effect and contribution varies with the size of the glucose challenge / the meal composition
vagal
![Page 6: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/6.jpg)
AMPLIFIER
SIGNAL AMPLIFICATION OUTPUT
GLUCOSE GLP-1 increasedFOOD AMPLIFICATION INSULIN*
(incret-ins) of glucose/meal-stimulatedinsulin secretion
Incretins regulate a proportional response
![Page 7: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/7.jpg)
What happens to theincretin effect in diabetes?
As a consequence of hyperglycaemia and/or other metabolic manifestations of diabetes itself incretin effect is reduced by ~50% in diabetes8
Normal secretion of GLP-1, but.. Down-regulation of GLP-1 receptor8
Less substrate to act on (β-cells, δ-cells, etc) Gastroparesis8
Resistance to GLP-1 (which needs pharmacological doses to overcome it)8,10
8. Nauck et al. Diabetologia (2013); 9. De Frionzo Diabetes (2009) 10. Vilsbøll T, et al. Diabetologia. (2002)
![Page 8: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/8.jpg)
AMPLIFIER
NO SIGNAL AMPLIFICATION NO OUTPUT
No GLUCOSE NO MORENO FOOD INSULIN GLP1
Incretins and hypoglycaemia
Reduced risk of hypoglycaemia
![Page 9: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/9.jpg)
No increase in insulin when glucose levels are low during a
continuous infusion of GLP-11
7. Nauck et al. JCEM (2002)
![Page 10: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/10.jpg)
What happens to -cells in diabetes?
8. Defronzo. Diabetes (2009)
Diabetes is associated with the blunting of hyperglycaemia or postprandial suppression of glucagon secretion
Reduced incretin effect Hyperplasia of -cells Increased sensitivity to glucagon
Contributes to the inappropriately increased rate of hepatic glucose output characteristic of T2DM
=ALPHA CELL ANARCHY
![Page 11: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/11.jpg)
α
β
GLP-1 in -cell biology3,4
L
MEAL
carbohydrate protein, fatty &
bile acids
GLPRGLP1
Distal small intestine ileum and colon
Pancreas
• Augmented suppression of glucagon release
• Partly via increased insulin
• Partly via somatostatin (?)
3. Campbell & Drucker. Cell Metabolism (2013); 4. Diakogiannaki, et al. Physiol. Behav. (2012).
vagal
vagal
![Page 12: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/12.jpg)
No impairment of glucagon response (which protects against hypoglycaemia)
during an infusion of GLP-1
7. Nauck et al. JCEM (2002)
ControlGLP-1
![Page 13: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/13.jpg)
Incretins in the stomach
L
MEAL
GLPRGLP1
Distal small intestine ileum and colon
Stomach
11. Shah & Vella Rev Endocr Metab Disord (2014); 12. Marathe et al. Diabetes Care (2013)
carbohydrate protein, fatty &
bile acids
FULL
vagal afferents
Reduced gut motility Delayed stomach emptying Delayed digestion and
absorption of carbohydrates2
![Page 14: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/14.jpg)
Exenatide slows emptying of the stomach as measured by the half-life of a 99TC -labelled meal13
13. Linnebjerg et al. Regl Pept (2008)
Placebo Exenatide (5µg) Exenatide (10µg)0
1
2
3
4
5
6
T(50
) h o
f lab
elle
d m
eal
*
*
![Page 15: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/15.jpg)
L
MEAL
GLPRGLP1
Distal small intestine ileum and colon
brain
Enhanced glucose disposal Increased satiety/fullness Reduced appetite Reduced food intake
2. Campbell & Drucker. Cell Metabolism (2013); 11. Shah & Vella Reviews in Endocrine and Metabolic Disorders (2014)
carbohydrate protein, fatty &
bile acidsvagal
Incretins in the brain
![Page 16: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/16.jpg)
Incretin biology and DPP4
L
MEAL
GLPRGLP1
Distal small intestine ileum and colon
2. Campbell & Drucker. Cell Metabolism (2013);
carbohydrate protein, fatty &
bile acids
vagal
• Pancreas
• Stomach
• Liver
• Brain
DPP4
Short circulating half life (<2 min)
![Page 17: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/17.jpg)
Resistant to DPP4
GLP1 has a 1-4 min half-life (designed for grazing?)
GLP1 (amidated form)
Rationale for GLP analoges1,2
DPP4
EXENATIDE
plasma half-life of 2.4 hours and an action time of about 6-8 hours
![Page 18: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/18.jpg)
The Gila monster
![Page 19: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/19.jpg)
“I want some of that (adaptation) for my patients”
From Lizard Saliva to Diabetes Drug
![Page 20: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/20.jpg)
![Page 21: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/21.jpg)
All lower the HbA1c by approximately the same amount when added-on metformin40 RCT (n=17795): 6-12 months trials, added-on after MFM failure
McIntosh B et al. Open Med 2011; 5:E35-E48
![Page 22: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/22.jpg)
Series1
-1
-0.5
0
0.5
+0.1 +0.1+0.2
-0.4*-0.5
† -0.6‡
-0.8*-0.9†
-0.8‡
Exenitide lowers HbA1cin both dual and triple therapy
N 113 110 113
Baseline 8.2 8.3 8.2
123 125 129
8.7 8.5 8.6
247 245 241
8.5 8.5 8.5
Ch
an
ge
in
Hb
A1c
*P<0.001 vs placebo †P<0.0002 vs placebo
30-week data; mean .
Placebo BID Exenatide 5 μg BID Exenatide 10 μg BID
‡P<0.0001 vs placebo
1. DeFronzo RA ,et al. Diabetes Care 2005;28:1092–100. 2. Buse JB, et al. Diabetes Care 2004;27:2628–35. 3. Kendall DM, et al. Diabetes Care 2005;28:1083–91.
Pivotal phase 3 clinical studies—combined intent-to-treat (ITT)
MET1 SU2 MET + SU3
![Page 23: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/23.jpg)
Exenatide was as effective as insulin at lowering HbA1c
Abbreviations: BL, baseline; MET, metformin, SU, sulphonylurea; TZD, thiazolidinedione
1. Nauck MA, et al. Diabetologia 2007; 50(2): 259–67. 2. Heine RJ, et al. Ann Intern Med 2005; 143(8): 559–69. 3. Barnett AH, et al. Clin Ther 2007; 29(11): 2333–48. 4. Davies MJ, et al. Diabetes Obes Metab 2009; 11(12): 1153–62. 5. Bunck MC, et al. Diabetes Care 2009; 32(5): 762–8.
Primary endpoint: Change in HbA1c (%)
Series1
-1.5
-1
-0.5
0
-1.0%-1.1%
-1.4% -1.3%
-0.8%-0.9%
-1.1%
-1.4% -1.3%
-0.7%
MET + SU1MET, SU, TZD
(combination of 2 or 3)4
n=253BL=8.6%
n=248BL=8.6%
n=275BL=8.2%
n=260BL=8.3%
N=68BL= 8.9%
n=118BL= 8.7%
n=116BL=8.5%
n=36BL= 7.6%
n=33BL= 7.4%
exenatide 10 µg BID plus orals Insulin aspart 70/30 Insulin glargine
Background
Ch
an
ge
in H
bA
1c
N=70BL= 9%
52 weeksMET + SU2
26 weeksMET or SU3
16 weeks 26 weeksMET5
52 weeks
![Page 24: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/24.jpg)
Starting GLP-1R agonistsCASE#1
![Page 25: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/25.jpg)
Laboratory parameters HbA1c 7.9% Total cholesterol: 3.8 mmol/L Normal albuminuria and
eGFR
Graham presents to his GPPatient history• Age 50 years• Married, 3 children• Works as a taxi driver• BP 132/85 mmHg• BMI 30 kg/m2
• Non-smoker• Diet and exercise not optimal
Medical history• Diabetes diagnosed 18 months ago
• Dyslipidaemia and hypertension diagnosed 3 years ago
Graham, aged 50
Current Medications• Metformin 1500 mg/day• Rosuvastatin 20 mg/day• Telmisartan/hydrochlorothiazide
80/12.5 mg fixed dose combination
![Page 26: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/26.jpg)
What are Graham’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
![Page 27: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/27.jpg)
What are Graham’s treatment priorities?
Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Weight
Cost
Question 1. How well will he tolerate an GLP-1R agonist?
Tolerability
![Page 28: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/28.jpg)
Common side effectsNausea (20-30%)
Vomiting (~10%)
Diarrhoea (~10%)
Injection site reactions
(10-20%)
![Page 29: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/29.jpg)
Nausea and vomiting with exenatide
Exenatide Exenatide LAR
attenuates slowly (weeks to months) attenuates rapidly (4-8 weeks)
![Page 30: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/30.jpg)
30
Tricks for tolerability
• Cautious dose escalation 5µg bd to 10µg bd
• Reducing the size as well as the fat content of meals can sometimes help get patients through.
• Although exenatide can be injected at any time within 60 minutes of meal, starting off at ~15 minutes prior meal and slowly extending this depending on tolerability can also help. Question 1a. What other tricks do you
have?
![Page 31: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/31.jpg)
What are Graham’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
Question 2. What about driving on a GLP-1RA?
![Page 32: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/32.jpg)
Meta-analysis: Overall hypoglycemia
for medications added-on metformin34 RCT (n=16704): 6-12 months trials, added-on after metformin failure
McIntosh B et al. Open Med 2011; 5:E35-E48
![Page 33: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/33.jpg)
33
GLP-1 actions on the β cell are normally tightly coupled to the level
of ambient glucose. The insulinotropic actions of GLP-1 are rapidly terminated once the plasma glucose falls into the normal range
7 6 5 4 3 2 1
GLP1 doesn’t cause hypoglycemia
![Page 34: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/34.jpg)
34
Closer to the edge, reduced food intake as well as
uncoupling of GLP-1 from its glucose dependence by
sulphonylureas
But they do make it easier for SUs to cause hypoglycemia
7 6 5 4 3 2 1
GLP-1RA
![Page 35: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/35.jpg)
35
Byetta added to metformin does not increase the risk of hypoglycaemia; with
SU consider dose reduction
0
10
20
30
40
EX + SU + MET3
(n=733; ITT population)
EX + SU1
(n=337; ITT population)
EX + MET2
(n=336; ITT population)
Inci
den
ce o
f h
ypo
gly
caem
ia (
%)
3%
14%
36%
13%
19%
28%
5% 5%
Placebo
30-Week, randomised, placebo-controlledExenatide 5 g
5%
Exenatide 10 g
1. Buse JB, et al. Diabetes Care. 2004; 27: 2628–35. 2. DeFronzo RA, et al. Diabetes Care. 2005; 28: 109–100. 3. Kendall DM, et al. Diabetes Care. 2005; 28: 1083–91.
![Page 36: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/36.jpg)
De Heer et al Diabetes 2007
GLP-1 in the presence of a sulfonylurea agent leads to enhanced insulin secretion
and suppressed glucagon even at normal or low glucose concentrations
GLP1
control
![Page 37: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/37.jpg)
What are Graham’s treatment priorities?
Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
Question 3. How will GLP-1R agonist affect his weight?
Weight Loss
![Page 38: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/38.jpg)
Meta-analysis: Body weight change
for medications added-on metformin30 RCT (n=15265): 6-12 months trials, added-on after MFM failure
McIntosh B et al. Open Med 2011; 5:E35-E48
![Page 39: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/39.jpg)
Exenatide 10 μg BID provided long-term glycaemic control without weight gain over 156 weeks*†
Changes in body weight1
-1
-2
-3
-4
-5
-6
-7
-8
-9
-10
0 26 52 78 104 130 156
‡P<0.0001
Mean baseline body weight: 99 ± 18 kg
reduction from baseline
-1.6 kgat week 12
reduction from baseline
-5.3 kgat 3 years
N=217
Ch
an
ge
in
bo
dy
we
igh
t (k
g)
Treatment (weeks)
*Of 527 subjects, 217 completed 156 weeks of the study, of which 84% lost weight and 50% lost at least 5% of baseline body weight.1
†Exenatide is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.
• Weight loss >1.5 kg per week has been observed in patients treated with exenatide2
• Weight loss of this rate may have harmful consequences2
‡
1. Klonoff DC et al. Curr Med Res Opin 2008; 24: 275–86. 2. Byetta Approved Product information 17 September2012 .
> 85% patients lose weight
![Page 40: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/40.jpg)
Potential for weight loss with Exenatideversus weight gain with insulin glargine
-3
-2
-1
0
1
2
Insulin glargineExenatide
Chan
ge in
bod
y w
eigh
t (kg
)
0 2 4 8 12 18 26Insulin glargine n = 267 266 261 253 251 246 244Byetta n = 281 277 275 261 245 235 231
*P < 0.0001 compared with insulin glargine measure at the same time point.
Weeks
**
**
**
Adapted from Heine RJ, et al. Ann Intern Med 2005; 143(8): 559–69.
†Exenatide is not indicated for the management of obesity, and weight change was a secondary endpoint in clinical trials.
(Mean baseline body weight 87.5 kg)
(Mean baseline body weight 88.3 kg)
![Page 41: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/41.jpg)
What are Graham’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
Q4. How well will an GLP-1RA keep working?
50 y.o.
![Page 42: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/42.jpg)
42
Exhaustion (nike effect)Sustainability – the NIKE effect
![Page 43: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/43.jpg)
Exenatide 10 μg BID provides sustained HbA1c reduction over 156 weeks*
Mean change in HbA1c from baseline10
9
8
7
6
5
4
3
2
1
0 26 52 78 104 130 156
†P<0.0001
Mean baseline HbA1c: 8.2%
reduction from baseline
-1.1%at week 12
reduction from baseline
-1.0%at 3 years
†
Me
an
Hb
A1c
(%
)
Treatment (weeks)
Adapted from Klonoff DC, et al. Curr Med Res Opin 2008; 24: 275–86.
*Of 527 subjects, 217 completed 156 weeks of the study, of which 46% achieved HbA1c of ≤7%.
N=217
![Page 44: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/44.jpg)
44
Five-Year Efficacy and Safety Data of Exenatide Once Weekly
DURATION1. Mayo Clin Proc (2015)
![Page 45: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/45.jpg)
What are Graham’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
Question 5. Will a GLP1RA protect his heart?
![Page 46: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/46.jpg)
CV Outcomes and GLP-1RA
2015 20172016 2018 201920132012 2014
ELIXALixisenatide(N = 6000)
LEADERLiraglutide (N = 9341)
EXSCELExenatide (N = 9500)
REWINDDulaglutide (N = 9622)
SUSTAIN-6Semaglutide (N = 3260)
![Page 47: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/47.jpg)
What are Graham’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
Cost
Compliance
Tolerability
CVD risk
Question 5. Is it subsidised?
![Page 48: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/48.jpg)
GLP-1RA in addition to insulin
CASE#2
![Page 49: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/49.jpg)
Laboratory parameters HbA1c 8.2% Total cholesterol: 5.8 mmol/L eGFR 125 ml/min/1.73m2
Kevin presents to his GPPatient history• Age 50 years• BP 142/75 mmHg• BMI 37 kg/m2
• Non-smoker• Diet and exercise not optimal
Medical history• Diabetes diagnosed 5 years ago• Failed oral therapy
Now on insulin injections
• But control is still suboptimal
Kevinaged 50
Current Medications• Metformin 2g/day• Insulin 100U/day• Rosuvastatin 20 mg/day• Telmisartan/hydrochlorothiazide
80/12.5 mg fixed dose combination
![Page 50: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/50.jpg)
What are Kevin’s treatment priorities?
Weight Sustainability
No HYPO
Lower HbA1c
CVD Risk
Compliance
Tolerability Cost
Q 6. How well will an GLP1RA work for Kevin(on top of his insulin regimen)?
![Page 51: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/51.jpg)
Over the past 3 years, however, the effectiveness of combining GLP-1 receptor agonists (both
shorter-acting and newer weekly formulations) with basal insulin has been demonstrated, with most studies showing equal or slightly superior
efficacy to the addition of prandial insulin, and with weight loss and less hypoglycemia.
The available data now suggest that either a GLP-1 receptor agonist or prandial insulin could be used
in this setting, with the former arguably safer, at least for short-term outcomes
Inzucchi Diabetes (2015)
![Page 52: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/52.jpg)
1. Buse JB, et al. Ann Intern Med 2011; 154: 103–12 ;
Exenatide lowers HbA1c when used in combination with basal insulin1
Exenatide
![Page 53: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/53.jpg)
1. Buse JB, et al. Ann Intern Med 2011; 154: 103–12.;.
No increased risk of weight gain or hypoglycaemia when exenatide is added to basal insulin1,2**†
Change in weight* Minor hypoglycaemia
Exenatide
![Page 54: ADEA CASE SERIES Merlin Thomas Gary Kilov Nicole Frayne Giuliana Murfet Facilitator: Rachel McKeown, Professional Services Manager, ADEA (NSW)](https://reader031.vdocuments.net/reader031/viewer/2022032708/56649e5d5503460f94b5653c/html5/thumbnails/54.jpg)
THANK YOU FOR YOUR PARTICIPATION
ADEA CASE SERIES
Merlin ThomasGary KilovNicole Frayne